Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | QRFPR | Q96P65 | 8/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | FCER2 | P06734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630682 | 0.94 | CTSB (0.51) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL29591024 | 0.91 | CTSB (0.49) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL31438238 | 0.89 | MME (0.52) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL30051999 | 0.89 | CTSB (0.55) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL29784971 | 0.89 | ALDH1A1 (0.52) | ALDH1A1RAB9AMMP1FCER2 | |
| SCHEMBL23142823 | 0.89 | CTSB (0.55) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL30051480 | 0.89 | CTSB (0.55) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL23142822 | 0.89 | CTSB (0.55) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL30111298 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1OPRK1QRFPR | |
| SCHEMBL29630352 | 0.88 | MME (0.48) | QRFPRCTSBALDH1A1MMP1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRD1 4566/4885OPRM1 4101/4885OPRK1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.